Massachusetts General Hospital Gynecologic Oncology

Topics

• Ovarian cancer diagnosis and treatment 341
• Endometrial and Cervical Cancer Treatments 294
• Cervical Cancer and HPV Research 74
• Uterine Myomas and Treatments 59
• BRCA gene mutations in cancer 30
• Gestational Trophoblastic Disease Studies 30
• Intraperitoneal and Appendiceal Malignancies 24
• Surgical Simulation and Training 24
• PARP inhibition in cancer therapy 21
• Cancer survivorship and care 19
• Economic and Financial Impacts of Cancer 19
• Global Cancer Incidence and Screening 17

Most cited

1. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 486 citations · Rachel Sisodia

2. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

   Lancet (London, England) · 2024 · 348 citations · Linda Duska

3. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 349 citations · Rachel Sisodia

4. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

   The New England journal of medicine · 2023 · 405 citations · Linda Duska

5. DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics.

   Nucleic acids research · 2021 · 505 citations · Alex Rosenthal

6. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 587 citations · Eric Eisenhauer